QuidelOrtho Business Summary

QuidelOrtho Corporation (QDEL) operates a high-margin "razor-blade" business model, deriving approximately 96% of its total revenue from recurring sales of proprietary consumables, reagents, and service contracts associated with its global installed base of diagnostic instruments. The company’s operations are structured into four primary segments: Labs (clinical chemistry and immunoassays), Point of Care (rapid infectious disease and cardiac testing), Immunohematology (blood typing and transfusion medicine), and Molecular Diagnostics. As of early 2026, the company is executing a strategic pivot toward non-respiratory growth to offset the normalization of COVID-19 testing volumes, leveraging its Sofia and VITROS platforms to capture market share in chronic disease and hospital-based testing. QuidelOrtho competes directly with global in vitro diagnostic (IVD) giants such as Abbott Laboratories, Roche Diagnostics, and Danaher (Beckman Coulter); it occupies a specialized market position as a leader in point-of-care accessibility and a dominant player in the transfusion medicine niche. Formed by the 2022 merger of Quidel (founded in 1979 by David Katz) and Ortho Clinical Diagnostics (a legacy Johnson & Johnson division established in 1939), the company is currently led by President and CEO Brian J. Blaser, a 25-year industry veteran who previously oversaw Abbott’s global diagnostics business. The executive leadership team includes CFO Joseph M. Busky, who is slated to retire in June 2026, and Jonathan Siegrist, the Head of Global R&D and former CTO of Cepheid, who directs the company’s technological innovation and product roadmap. The Board of Directors is chaired by Kenneth F. Buechler, Ph.D., a co-founder of Biosite, and includes notable members such as John R. Chiminski (former CEO of Catalent) and Evelyn Dilsaver (former CEO of Charles Schwab Investment Management). QuidelOrtho maintains a strong institutional investor base, with Vanguard Group, BlackRock, and T. Rowe Price collectively holding a majority of the company’s outstanding shares.